Xanthogranulomatous Cystitis / 대한비뇨기과학회지

Xanthogranulomatous cystitis is a rare benign chronic inflammatory disease of unknown etiology. Herein, an extensive case presenting as a mass around the dome of bladder, with infiltration of perivesical fat and a part of omentum, is reported.

Comparison of the Surgical Outcome between Onlay Island Flap and Tubularized Incised Plate Urethroplasty in Hypospadias Repair / 대한비뇨기과학회지

PURPOSE: The onlay island flap and tubularized incised plate (TIP) urethroplasty commonly preserve the urethral plate during each procedure, but there is a dearth of comparative data. Thus, we retrospectively reviewed our clinical data to compare the surgical outcome of the onlay and TIP urethroplasty for hypospadias correction. MATERIALS AND METHODS: We performed onlay urethroplasty in 23 patients and TIP urethroplasty in 28 patients between 1995 and 2002. The age at the time of surgery, operation time, postoperative complications, and the duration for the development of complications in each procedure were compared. RESULTS: Among the 28 cases of TIP urethroplasty, 21 were primary, 6 were secondary, and the last case was a tertiary repair, while all of the 23 cases of onlay urethroplasty were primary (age range: 8 month to 11 year). The most common complication in both procedures was urethrocutaneous fistula. Residual curvature was more common in the onlay urethroplasty group. Delayed complications, which developed later than 6 months after surgery, were 30% in both groups. The success rate was similar between the two groups, but the TIP urethroplasty group illustrated a significantly shorter operation time than the onlay group. CONCLUSIONS: The most common complication was fistula in both the onlay and TIP urethroplasty groups. Even though the success rate was similar in both groups, the operation time of the TIP urethroplasty group was shorter than that of the onlay group. Also, the TIP urethroplasty procedure resulted in more acceptable cosmetic results including a slit like neourethral meatus.

Predictive Factor for the Early Progression of Androgen Independent Prostate Cancer in Intermittent Androgen Deprivation Therapy / 대한비뇨기과학회지

PURPOSE: The purpose of this study was to define the predictive factors for the early progression of androgen independent prostate cancer in patients receiving intermittent androgen deprivation (IAD) therapy. MATERIALS AND METHODS: A total of 101 patients (stages A to C in 29 and stage D in 72), who had completed at least 1 cycle of IAD, were included. A variety of possible prognostic factors, such as age, initial prostate-specific antigen (PSA) and testosterone, Gleason score, lymph node or bone metastasis, nadir PSA and testosterone, duration to nadir PSA, duration of off treatment, and ECOG performance index were analyzed using uni- and multivariate tests. RESULTS: Patients had completed at least one, and up to six, treatment cycles with a median follow-up of 43 (13-100) months. The median nadir PSA levels were 0.28, 0.41, 0.71, 0.88, 1.85 and 0.79ng/ml for cycles 1 to 6 (median 4.6 months), respectively. The median one cycle duration (on off treatment) was 14 months, 44% of that time spent off treatment, but the off treatment duration decreased with increasing number of treatment cycles. A total of 42 patients progressed to androgen independent prostate cancer, and the progression free rates at 36 and 60 months were 72 and 52%, respectively, according to the Kaplan-Meier method. Using multivariate analysis, the nadir PSA (p=0.044), ECOG performance index (p= 0.039) and lymph node or bone metastasis (p=0.03) were the strongest predictors for the progression of androgen independent prostate cancer. CONCLUSIONS: On receiving IAD, prostate cancer patients with lymph node or bone metastasis, a poor performance status and comparatively higher serum PSA nadir value after the first treatment phase, there is a high possibility for the early progression of androgen independent prostate cancer.

Intermittent Androgen Deprivation(IAD) with Cyproterone Acetate Monotherapy for Prostate Cancer: A preliminary report / 대한비뇨기과학회지

PURPOSE: The purpose of this study was to evaluate the feasibility of using IAD, as a steroidal antiandrogen (cyproterone acetate) monotherapy, for prostate cancer. MATERIALS AND METHODS: A total of 43 prostate cancer patients (Stage A to C in 27, D1 in 2 and D2 in 14) were reviewed. Androgen deprivation, with cyproterone acetate (200-300mg P.O/day), was continued until a serum prostate specific antigen (PSA) nadir was maintained for at least 3 months. Medication was then discontinued until the serum PSA reached a predetermined level. This cycle of treatment was repeated until there was a continual increase in the PSA irrespective of the medication. RESULTS: The mean observation period was 10.5 months, ranging from 4 to 28 months. In seven of the 43 patients, there was treatment failure before entering the off-treatment period of the 1st cycle. 17 of the remaining 36 patients completed the on-treatment during cycle 1, with a median time to PSA nadir of 4 months. Seven patients completed cycle 1, with a median time off-treatment of 5 months (43% of the treatment cycle). Nineteen patients are still in the on-treatment intervals and 10 in the off-treatment intervals of their first cycles. Two patients completed the on-treatment of the 2nd cycle, with a median time to PSA nadir of 2.5 months. During the off-treatment interval, most patients reported an improvement in the symptoms associated with androgen suppression. CONCLUSIONS: IAD, using cyproterone acetate monotherapy, is a feasible alternative for continuous androgen deprivation in the treatment of prostate cancer. It also results in the reduction of toxicity, cost of treatment and possibly a delay in the tumor progression.